The Effect of Left Ventricular Assist Device Therapy in Patients with Heart Failure and Mixed Pulmonary Hypertension

2017 ◽  
Vol 40 (2) ◽  
pp. 67-73 ◽  
Author(s):  
Hoong S. Lim ◽  
Neil Howell ◽  
Aaron Ranasinghe

Background Diastolic pressure gradient (DPG) of ≥7 mmHg has been proposed to distinguish mixed pulmonary hypertension from isolated post-capillary pulmonary hypertension in heart failure (HF). We evaluated the changes in pulmonary hemodynamics with left ventricular assist devices (LVADs) in patients with DPG of ≥7 or <7 mmHg, and effects on peak oxygen uptake (VO2) in patients with advanced HF. Methods Pre- and post-LVAD implant pulmonary hemodynamics (including right atrial (RA) pressures, DPG, pulmonary vascular resistance (PVR), pulmonary capacitance (PCap) and cardiac output), echocardiography, cardiopulmonary exercise test were measured in 38 consecutive patients. Results Ten of 38 patients had baseline DPG ≥7 mmHg. There were no significant difference in baseline characteristics, peak VO2 and ventilation slope, but PVR were higher, and PCap lower in patients with DPG ≥7 mmHg. Pulmonary artery pressures improved in all patients, but PVR and DPG remained higher and PCap lower in patients with baseline DPG ≥7 mmHg after a median follow-up of 181 (IQR 153–193) days. Peak VO2 increased and ventilation slope reduced post-LVAD, and these improvements were comparable between groups. Only RA pressure reduction and exercise increase in heart rate were significant predictors of peak VO2 increase on multivariate analysis. Conclusions Baseline DPG of ≥7 mmHg compared to DPG <7 mmHg have persistently lower PCap and higher PVR post-LVAD, but the increase in peak VO2 was comparable despite these residual pulmonary vascular abnormalities. The improvement in peak VO2 was related to reduction in right atrial pressure and exercise increase in heart rate.

2018 ◽  
Author(s):  
Gaurang Vaidya ◽  
Emma Birks ◽  
Jessica Pillarella ◽  
Benjamin Salgado ◽  
Rajakrishnan Vijayakrishnan ◽  
...  

Background While Beta blockers(BB) and Angiotensin system blockers(ACEinh/ARB) are important components in advanced heart failure therapy, their use after left ventricular assist device (LVAD) implantation remains controversial. Concern has been raised about possible adverse effects of BB on right ventricular(RV) function while tolerance and efficacy/outcome data for ACEinh are lacking. This study aimed to characterize the use of medical therapy post-LVAD implantation and to evaluate its safety and efficacy. Methods Demographic, clinical and echocardiographic variables of patients implanted with a continuous-flow LVAD between 2012 and 2015 at a single center were retrospectively reviewed. Mortality and heart failure(CHF) hospitalizations were followed from 6-18 months’ post-implant. Results Of a total of 98 patients, the mean age was 57 years, 81% were men and 61% had ischemic disease. While the use of diuretics decreased considerably post LVAD, over 50% continued to require diuretics. At 6th month post-implantation, 73% of patients were on BB, and these patients had significantly lower proBNP at 6 and 12 months follow up. Despite significant prevalence of RV dysfunction in the cohort (>75% at 6 months), there was no significant difference in CHF hospitalizations based on BB use (14% vs 15%) and instead a trend towards less deaths in those on BB (6% vs 15%). ACEinh/ARB use was likewise common at 6 month (61%) and these patients had lower proBNP at 6 and 12 months, lower right atrial(RA) pressures (9 vs 12 mmHg, p=0.03), and a significantly lower mortality—a finding which remained on multivariate analysis. Conclusion The use of ACEinh/ARB appeared to be associated with subsequent improved survival, lower proBNP and RA pressures. The use of BB post-LVAD appears safe and was associated with a lower proBNP, even in a patient population with a significant prevalence of RV dysfunction.


Sign in / Sign up

Export Citation Format

Share Document